A Prospective Study To Identify Predictive Biological Markers In Blood And Cyst Fluid Aspirates From Patients With Pancreatic Cyst Lesions
Launched by THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER, HOUSTON · Jan 4, 2016
Trial Information
Current as of July 09, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying pancreatic cystic lesions, which are fluid-filled sacs in the pancreas. The goal is to find out if certain biological markers in blood and cyst fluid can help diagnose these lesions better. The study will involve patients who have been diagnosed with pancreatic cystic lesions and are undergoing a procedure to remove some fluid from the cysts for testing. Over the next ten years, researchers will collect various health information, including blood samples and details from medical imaging to see how these lesions change over time.
To participate, individuals must have been diagnosed with pancreatic cystic lesions, acute or chronic pancreatitis, pancreatic cancer, or certain developmental issues with the pancreas. They should be able to provide written consent for the use of their blood and cyst fluid samples. While the study involves some minor risks, like discomfort from blood draws, there are no additional medical benefits provided to participants beyond standard care. However, the knowledge gained from this study could potentially help future patients with similar conditions.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Diagnosis of Pancreatic Cystic Lesions (PCLs) or Acute Pancreatitis (AP) or chronic pancreatitis(CP) or Pancreatic Cancer (PC) (any stage/grade) or congenital developmental anomalies of the pancreas.
- • Any combination of the diagnoses above.
- • Patients must provide written informed consent for the collection of blood specimens for research purposes.
- • Patients with PCLs must provide informed consent for collection of excess cyst fluid aspirate remaining after testing for routine standard of care
- • Patients with pancreatic Cystic Lesions (PCLs) or AP or CP or PC (any stage/grade) or congenital developmental anomalies of the pancreas undergoing surgery must provide informed consent for collection of surgical specimen
- Exclusion Criteria:
- • Patients with co-existing malignancies of other organs (or prior history of such)
- • Patients unable to provide informed consent
- • Patients unable to complete follow up
About The University Of Texas Health Science Center, Houston
The University of Texas Health Science Center at Houston (UTHealth) is a leading academic institution dedicated to advancing health through education, research, and clinical practice. As a prominent sponsor of clinical trials, UTHealth leverages its extensive resources and expertise in biomedical research to facilitate innovative studies aimed at improving patient outcomes. The institution is committed to fostering a collaborative environment that promotes scientific discovery and the translation of research findings into effective healthcare solutions, all while adhering to the highest ethical standards and regulatory guidelines. With a multidisciplinary approach, UTHealth plays a critical role in addressing complex health challenges and enhancing the quality of life in diverse communities.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Houston, Texas, United States
Patients applied
Trial Officials
Nirav C Thosani, MD MHA
Principal Investigator
The University of Texas Health Science Center, Houston
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials